Preventive cardiology| Volume 110, ISSUE 5, P662-665, September 01, 2012

Download started.


Evaluation of Low-Density Lipoprotein Particle Number Distribution in Patients With Type 2 Diabetes Mellitus With Low-Density Lipoprotein Cholesterol <50 mg/dl and Non-High-Density Lipoprotein Cholesterol <80 mg/dl

      Many patients with type 2 diabetes mellitus (T2DM) have relatively normal levels of low-density lipoprotein (LDL) cholesterol yet have increased risk for cardiovascular events. Distribution of lipoprotein subclasses in patients with T2DM who have achieved very low levels of LDL cholesterol (<50 mg/dl) or non–high-density lipoprotein (HDL) cholesterol (<80 mg/dl) have not been extensively examined. The aim of this study was to assess variations in lipoprotein particle concentration in patients with diabetes with “very low” LDL cholesterol and non-HDL cholesterol levels to elucidate the drivers of residual cardiovascular risk. Data were selected from a single large clinical laboratory database. Cases were patients with T2DM diagnosis codes (International Classification of Diseases, Ninth Revision, codes 250 to 250.93). Lipoprotein particle concentrations were analyzed using nuclear magnetic resonance spectroscopy. The Friedewald equation was used to calculate LDL cholesterol. Among the 1,970 patients with T2DM, the mean age was 61 years, and approximately 51% were men. At LDL cholesterol concentrations <50 mg/dl (triglyceride <150 mg/dl and HDL cholesterol >40 mg/dl), 16% had LDL particle concentrations <500 nmol/L, 70% had concentrations of 500 to 1,000 nmol/L, and 14% had concentrations >1,001 nmol/L. At non-HDL cholesterol levels <80 mg/dl, 8% had LDL particle concentrations <500 nmol/L, 67% had concentrations of 500 to 1,000 nmol/L, and 25% had concentrations >1,001 nmol/L. In conclusion, despite attainment of LDL cholesterol <50 mg/dl or non-HDL cholesterol <80 mg/dl, patients with diabetes exhibited significant variation in LDL particle levels, with most having LDL particle concentrations >500 nmol/L, suggesting the persistence of potential residual coronary heart disease risk.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brunzell J.D.
        • Davidson M.
        • Furberg C.D.
        • Goldberg R.B.
        • Howard B.V.
        • Stein J.H.
        • Witztum J.L.
        Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology foundation.
        Diabetes Care. 2008; 31: 811-822
        • Blonde L.
        State of diabetes care in the United States.
        Am J Manag Care. 2007; 13: S36-S40
      1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report.
        Circulation. 2002; 106: 3143-3421
        • American Diabetes Association
        Diagnosis and classification of diabetes mellitus (position statement).
        Diabetes Care. 2009; 32: S62-S67
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial.
        Lancet. 2003; 361: 2005-2016
        • Jeyarajah E.
        • Cromwell W.
        • Otvos J.
        Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.
        Clin Lab Med. 2006; 26: 847-870
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Otvos J.D.
        • Mora S.
        • Shalaurova I.
        • Greenland P.
        • Mackey R.H.
        • Goff D.C.
        Clinical implications of discordance between low-density lipoprotein cholesterol and particle number.
        J Clin Lipidol. 2011; 5: 105-113
        • O'Keefe J.H.
        • Cordain L.
        • Harris W.H.
        • Moe R.M.
        • Vogel R.
        Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.
        J Am Call Cardiol. 2004; 43: 2142-2146
        • Cromwell W.C.
        • Otvos J.D.
        LDL particle number is highly heterogeneous among patients with type 2 diabetes at an LDL cholesterol target goal <100 mg/dl.
        Am J Cardiol. 2006; 98: 1599-1602
        • Cromwell W.C.
        • Otvos J.D.
        • Keyes M.
        • Pencina M.
        • Sullivan L.
        • Vasan R.
        • Wilson P.
        • D'Agostino R.
        LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—implications for LDL management.
        J Clin Lipidol. 2007; 1: 583-592
        • Davidson M.H.
        • Ballantyne C.M.
        • Jacobson T.A.
        • Bittner V.A.
        • Braun L.T.
        • Brown A.S.
        • Brown W.V.
        • Cromwell W.
        • Goldberg R.B.
        • McKenney J.M.
        • Remaley A.T.
        • Sniderman A.D.
        • Toth P.P.
        • Tsimikas S.
        • Ziajka P.E.
        Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
        J Clin Lipidol. 2011; 5: 338-367
        • Gleeson R.
        • Davidson M.
        Lipidology a Primer: The What, Why, and How of Better Lipid Management. Prevent CVD Publishing, Madison, Wisconsin2010: 15-29